AR057824A1 - Sulfonilpirroles; composicion farmaceutica y uso del compuesto para prepararlas - Google Patents

Sulfonilpirroles; composicion farmaceutica y uso del compuesto para prepararlas

Info

Publication number
AR057824A1
AR057824A1 ARP060104135A ARP060104135A AR057824A1 AR 057824 A1 AR057824 A1 AR 057824A1 AR P060104135 A ARP060104135 A AR P060104135A AR P060104135 A ARP060104135 A AR P060104135A AR 057824 A1 AR057824 A1 AR 057824A1
Authority
AR
Argentina
Prior art keywords
acid
salt
hydroxy
acrylamide
pyrrol
Prior art date
Application number
ARP060104135A
Other languages
English (en)
Inventor
Thomas Bar
Thomas Maier
Thomas Beckers
Rolf-Peter Hummel
Martin Feth
Matthias Muller
Jurgen Volz
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of AR057824A1 publication Critical patent/AR057824A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Estos compuestos resultan utiles en la terapia del cáncer. Reivindicacion 1: Una sal de un compuesto seleccionado de: (E)-3-[1-(bifenil-4-sulfonil)-1H-pirrol-3-il]-N-hidroxi-acrilamida; (E)-N- hidroxi-3-(1-[4-(([2-(1H-indol-2-il)-etil]-metil-amino)- metil)-bencensulfonil]-1H-pirrol-3-il)-acrilamida; (E)-3-[1-(4-dimetilaminometil- bencensulfonil)-1H-pirrol-3-il]-N-hidroxi-acrilamida; y (E)-N-hidroxi-3-[1-(5-piridin-2-il-tiofen-2-sulfonil)-1H-pirrol-3-il]-acrilamida, con un ácido seleccionado del grupo que comprende: ácido bromohídrico, ácido fosforico, ácido nítrico, ácido sulfurico, ácido acético, ácido cítrico, ácido D- gluconico, ácido benzoico, ácido 2-(4-hidroxibenzoil)benzoico, ácido butírico, ácido sulfosalicílico, ácido maleico, ácido láurico, ácido málico como por ejemplo ácido (-)-L-málico o ácido (+)-D-málico, ácido fumárico, ácido succínico, ácido oxálico, ácido tartático como por ejemplo ácido (+)-L-tartárico o ácido (-)-D-tartárico o ácido mesotartárico, ácido embonico, ácido esteárico, ácido toluensulfonico, ácido metansulfonico, ácido 3-hidroxi-2-naftolico, ácido adípico, ácido L-ascorbico, ácido L-aspártico, ácido bencensulfonico, ácido 4-acetamido-benzoico, ácido (+)- canforico, ácido (+)-canfor-10- sulfonico, ácido caprílico (ácido octanoico), ácido dodecilsulfonico, ácido etan-1,2-disulfonico, ácido etansulfonico, ácido 2-hidroxi-etansulfonico, ácido formico, ácido galactárico, ácido gentísico, ácido D-glucoheptonico, ácido D-glucuronico, ácido glutámico, ácido 2-oxo-glutárico, ácido hipurico, ácido láctico como por ejemplo ácido D-láctico o ácido L-láctico, ácido malonico, ácido mandélico como por ejemplo ácido (+)-mandélico o ácido (-)-mandélico, ácido naftalen-1,5-disulfonico, ácido naftalen-2-sulfonico, ácido nicotínico, ácido palmítico, ácido piroglutámico como por ejemplo ácido L-piroglutámico, ácido yohídrico, ácido ciclámico, ácido tiociánico, ácido 2,2-dicloroacético, ácido glicerofosforico, ácido 1-hidroxi-2- naftoico, ácido salicílico, ácido 4-aminosalicílico, ácido glicolico, ácido oleico, ácido glutárico, ácido cinámico, ácido capronico, ácido isobutírico, ácido propionico, ácido cáprico, ácido undecilénico y ácido orotico, con una base seleccionado del grupo que comprende: una sal sodio, una sal de guanidinio, una sal de litio, una sal de magnesio, una sal de calcio, una sal de potasio, una sal férrica, una sal de amonio y una sal de trietilamonio; o un hidrato de ellos.
ARP060104135A 2005-09-21 2006-09-21 Sulfonilpirroles; composicion farmaceutica y uso del compuesto para prepararlas AR057824A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05108728 2005-09-21

Publications (1)

Publication Number Publication Date
AR057824A1 true AR057824A1 (es) 2007-12-19

Family

ID=37035343

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104135A AR057824A1 (es) 2005-09-21 2006-09-21 Sulfonilpirroles; composicion farmaceutica y uso del compuesto para prepararlas

Country Status (26)

Country Link
US (1) US8232297B2 (es)
EP (1) EP1928872B1 (es)
JP (1) JP5305910B2 (es)
KR (1) KR101256846B1 (es)
CN (1) CN101268070B (es)
AR (1) AR057824A1 (es)
AT (1) ATE549333T1 (es)
AU (1) AU2006298882B2 (es)
BR (1) BRPI0617167B8 (es)
CA (1) CA2622673C (es)
CY (1) CY1112780T1 (es)
DK (1) DK1928872T3 (es)
EA (1) EA016345B1 (es)
ES (1) ES2381962T3 (es)
HK (1) HK1124320A1 (es)
HR (1) HRP20120399T1 (es)
IL (1) IL189782A (es)
NO (1) NO341744B1 (es)
NZ (1) NZ566074A (es)
PL (1) PL1928872T3 (es)
PT (1) PT1928872E (es)
RS (1) RS52383B (es)
SI (1) SI1928872T1 (es)
TW (1) TWI406846B (es)
WO (1) WO2007039404A1 (es)
ZA (1) ZA200801394B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2725000A (en) 1999-01-13 2000-08-01 Bayer Corporation Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
ME02122B (me) 2004-03-11 2014-02-28 Altana Pharma Ag Sulfonilpiroli kao inhibitori hdac
JP5119143B2 (ja) 2005-03-15 2013-01-16 フォーエスシー アクチエンゲゼルシャフト Ｎ−スルホニルピロール類及びヒストンデアセチラーゼインヒビターとしてのそれらの使用
CN101268070B (zh) 2005-09-21 2012-09-05 奈科明有限责任公司 作为hdac抑制剂的磺酰基吡咯
EP1928826B1 (en) * 2005-09-21 2013-04-24 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
EP2100878A1 (en) 2008-03-12 2009-09-16 4Sc Ag Novel method for the production of sulphonylpyrroles as HDAC inhibitors
EP2100882A1 (en) * 2008-03-12 2009-09-16 4Sc Ag (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts
ES2620027T3 (es) 2008-09-03 2017-06-27 Biomarin Pharmaceutical Inc. Composiciones que incluyen derivados del ácido 6-aminohexanoico como inhibidores de HDAC
CA3061239A1 (en) 2011-02-28 2012-09-07 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EA201490644A1 (ru) * 2011-09-30 2014-09-30 Дана-Фарбер Кэнсер Инститьют, Инк. Терапевтические пептиды
US20150045367A1 (en) * 2011-12-29 2015-02-12 Pharmacyclics, Inc. Cinnamic acid hydroxyamides as inhibitors of histone deacetylase 8
CN110194748A (zh) 2012-01-13 2019-09-03 艾森生物科学公司 杂环化合物及其作为抗癌药的用途
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
CN107266453B (zh) * 2012-08-06 2020-02-07 艾森医药公司 作为蛋白激酶抑制剂的吡咯并嘧啶化合物
CA2903490C (en) 2013-03-15 2021-04-13 Biomarin Pharmaceutical Inc. Hdac inhibitors
BR112016000195A8 (pt) 2013-07-11 2019-12-31 Acea Biosciences Inc compostos heterocíclicos, composição farmacêutica, combinação, seu uso, e método para inibir uma atividade da tirosina quinase btk ou jak, egfr, alk, pdgfr, blk, bmx/etk, flt3(d835y), itk, tec, txk, e suas respectivas vias
JP6889494B2 (ja) 2015-10-09 2021-06-18 エイシア セラピューティクス， インコーポレイテッド ピロロピリミジンキナーゼ阻害剤の薬学的塩、物理的形態、および組成物、ならびにそれらを作製する方法
CN105622680B (zh) * 2015-12-22 2018-01-19 杭州卢普生物科技有限公司 一种舒尼替尼衍生物及其制备方法和应用
KR20180130565A (ko) 2016-04-14 2018-12-07 4에스체 악티엔게젤샤프트 아시아 환자에서의 레스미노스타트의 의학적 적용
BR112019020840A2 (pt) 2017-04-07 2020-04-28 Acea Therapeutics Inc sais farmacêuticos, formas físicas e composições de inibidores da pirrolopirimidina quinase e métodos de produção dos mesmos
TW201912183A (zh) 2017-08-31 2019-04-01 德商４Ｓｃ製藥公司 Hdac抑制劑與抗代謝藥劑組合用於癌症治療
CN110496136A (zh) * 2018-05-17 2019-11-26 王孝恩 锂制剂在制备治疗或预防癌症药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960787A (en) 1989-02-06 1990-10-02 Ciba-Geigy Corporation Certain pyrrolyl-substituted hydroxamic acid derivatives
JP3342485B2 (ja) 1991-12-10 2002-11-11 塩野義製薬株式会社 芳香族スルホンアミド系ヒドロキサム酸誘導体
WO1996038418A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
KR20020070285A (ko) 1999-11-23 2002-09-05 메틸진, 인크. 히스톤 디아세틸라제의 억제제
WO2001038323A1 (en) 1999-11-23 2001-05-31 Merck & Co., Inc. Pyrazinone thrombin inhibitors
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
EP1431267A4 (en) 2001-08-09 2004-12-22 Ono Pharmaceutical Co COMPOUNDS DERIVED FROM CARBOXYLIC ACID AND MEDICAMENTS COMPRISING SUCH COMPOUNDS AS ACTIVE INGREDIENT
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
EP1429765A2 (en) 2001-09-14 2004-06-23 Methylgene, Inc. Inhibitors of histone deacetylase
US7482488B2 (en) 2002-08-29 2009-01-27 Temple University - Of The Commonwealth System Of Higher Education Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
AU2004268621C1 (en) 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
EP1709007A1 (en) 2004-01-22 2006-10-11 Altana Pharma AG N-4-(6-(heteo)aryl-pyrimidin-4-ylaminophenyl)-benzenesulfonamides as kinase inhibitors
US20050197336A1 (en) 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
ME02122B (me) 2004-03-11 2014-02-28 Altana Pharma Ag Sulfonilpiroli kao inhibitori hdac
US7345043B2 (en) 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
US7432808B2 (en) 2004-12-15 2008-10-07 Intel Corporation Wireless module enabled component carrier for parts inventory and tracking
JP5119143B2 (ja) 2005-03-15 2013-01-16 フォーエスシー アクチエンゲゼルシャフト Ｎ−スルホニルピロール類及びヒストンデアセチラーゼインヒビターとしてのそれらの使用
JP5054671B2 (ja) * 2005-04-07 2012-10-24 フォーエスシー アクチエンゲゼルシャフト ヒストンデアセチラーゼインヒビターとしてのスルホニルピロール
CN101268070B (zh) 2005-09-21 2012-09-05 奈科明有限责任公司 作为hdac抑制剂的磺酰基吡咯
EP1928826B1 (en) * 2005-09-21 2013-04-24 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors

Also Published As

Publication number Publication date
DK1928872T3 (da) 2012-05-07
RS52383B (en) 2012-12-31
BRPI0617167B1 (pt) 2021-02-09
NO341744B1 (no) 2018-01-15
IL189782A0 (en) 2008-08-07
PL1928872T3 (pl) 2012-08-31
TWI406846B (zh) 2013-09-01
EP1928872A1 (en) 2008-06-11
HK1124320A1 (en) 2009-07-10
TW200745028A (en) 2007-12-16
ATE549333T1 (de) 2012-03-15
BRPI0617167B8 (pt) 2021-05-25
ZA200801394B (en) 2009-12-30
HRP20120399T1 (hr) 2012-06-30
KR101256846B1 (ko) 2013-04-24
IL189782A (en) 2013-06-27
ES2381962T3 (es) 2012-06-04
US20090263353A1 (en) 2009-10-22
AU2006298882A1 (en) 2007-04-12
EP1928872B1 (en) 2012-03-14
CN101268070B (zh) 2012-09-05
CA2622673A1 (en) 2007-04-12
EA016345B1 (ru) 2012-04-30
CA2622673C (en) 2017-06-27
PT1928872E (pt) 2012-05-25
CY1112780T1 (el) 2016-02-10
KR20080047607A (ko) 2008-05-29
US8232297B2 (en) 2012-07-31
BRPI0617167A2 (pt) 2011-07-12
WO2007039404A1 (en) 2007-04-12
NZ566074A (en) 2011-08-26
SI1928872T1 (sl) 2012-06-29
NO20081797L (no) 2008-04-17
CN101268070A (zh) 2008-09-17
JP5305910B2 (ja) 2013-10-02
AU2006298882B2 (en) 2011-10-27
JP2009508826A (ja) 2009-03-05
EA200800700A1 (ru) 2009-04-28

Similar Documents

Publication Publication Date Title
AR057824A1 (es) Sulfonilpirroles; composicion farmaceutica y uso del compuesto para prepararlas
RU2012117797A (ru) Ингибитор гепараназной активности
NZ593061A (en) Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -azetidine-3-carboxylic acid
CL2009000870A1 (es) Compuestos derivados de acidos p-1,3,4-oxadiazolil-2-il-fenilboronicos, inhibidores de amida hidrolasa de acido graso (faah); composicion farmaceutica, utiles para tratar una afeccion, enfermedad o trastorno doloroso, inflamatorio, inmunologico, entre otros.
NO343857B1 (no) Immunresponsmodifiserende skumformuleringer
PE20161247A1 (es) Benzamidas sustituidas y metodos para usarlas
NZ607794A (en) N-acylsulfonamide apoptosis promoters
AR055647A1 (es) Derivados de n-sulfonilpirrol como inhibidores de hdac, sus sales cristalinas, metodos para su preparacion y polimorfos de los mismos, composiciones farmaceuticas que los contienen y su uso en combinacion con agentes anticancer para el tratamiento de la neoplasia.
AR043833A1 (es) Derivados de 1,2 diazol. metodo de preparacion y composiciones farmaceuticas
RU2012158142A (ru) Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
PE20180575A1 (es) Benzamidas sustituidas y metodos para utilizarlas
JP2012508760A (ja) ４−［２−（２−フルオロフェノキシメチル）フェニル］ピペリジン化合物の結晶形態
NO20085052L (no) 4-((fluorofenoksyl)fenylmetyl)piperidin metansulfonat: anvendelser, synteseprosess og farmasoytiske sammensetninger
NZ705813A (en) Treatment of mild and moderate alzheimer’s disease
PE20061390A1 (es) Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la produccion de las mismas
JP5769348B2 (ja) １−（２−フェノキシメチルヘテロアリール）ピペリジン化合物および１−（２−フェノキシメチルヘテロアリール）ピペラジン化合物
JP2015528515A5 (es)
Gruner et al. Characterization of pharmacological and wake-promoting properties of the dopaminergic stimulant sydnocarb in rats
EA200870543A1 (ru) Нежелательные примеси к донепезилу
RU2010145064A (ru) Сухая композиция трансглутаминазы
Männistö et al. Effect of lithium on the analgesia caused by morphine and two antidepressants in mice
JP6259117B2 (ja) 経皮吸収組成物
RU2010135794A (ru) Амиды 3-(4-фторфенил)-3-гидрокси-2-аминопропионовой кислоты и родственные соединения, обладающие обезболивающим действием
RU2547830C2 (ru) Сокристаллы трамадола и коксибов
RU2007108850A (ru) Способ получения ингибиторов кислотной коррозии

Legal Events

Date Code Title Description
FG Grant, registration